Technology selection identified as biggest hurdle in serialization race for compliance
Resourcing the deployment of serialization systems and processes also cited as a significant barrier to compliance with European FMD,
New industry research explores the greatest barriers to serialization success as companies across the pharmaceutical supply chain prepare for new regulations in the US and Europe.
The research, conducted by serialization system provider SEA Vision and life science technology specialist Zenith Technologies, highlights technology selection as the biggest challenge currently faced by the industry, cited by 28% of respondents.
As the industry considers the implications of the European Falsified Medicines Directive (FMD), one quarter of respondents rated understanding global serialization requirements as the biggest challenge they face. Fourteen percent are most concerned by the tight deployment timescales, while 12% believe that resourcing the deployment of serialization systems and processes is the biggest barrier to compliance.
Other cited challenges include establishing lifecycle support for their systems (7%) and selecting an implementation partner (7%).
Commenting on the research, Carlos Machado, serialization director at SEA Vision US, said: “Preparing for serialization is a complex task and it is clear that the challenges that companies must overcome are wide ranging.
“Technology selection and implementation is key to project success, and flexibility and scalability are important factors to consider when selecting a serialization solution that is built for the future. Given the multiple technical and logistical challenges associated with implementing a solution, reputable providers should be able to demonstrate a concrete track record of working across varying global serialization architectures. We expect to see a growing reliance on third party support providers over the coming months as many pharmaceutical manufacturers lack the internal resource and expertise to face the challenge of serialization head on.”
In 2016, SEA Vision and Zenith Technologies formed a global partnership to support pharmaceutical companies with the impending challenge of installing and integrating serialization across drug manufacturing sites.
The collaboration brings together Italian-based SEA Vision’s serialization system along with global Zenith Technologies’ ability to integrate systems and deliver ongoing technical support at a local level.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance